The Clinical and Economic Burden of Nonadherence with Antihypertensive and Lipid-Lowering Therapy in Hypertensive Patients  by Cherry, Spencer B. et al.
The Clinical and Economic Burden of Nonadherence
with Antihypertensive and Lipid-LoweringTherapy in
Hypertensive Patients
Spencer B. Cherry, MBA,1 Joshua S. Benner, PharmD, ScD,1,2 Mohamed A. Hussein, PhD,1
Simon S. K. Tang, MPH,3 Michael B. Nichol, PhD4
1Health Economics & Outcomes Research, IMS Health, Falls Church,VA, USA; 2Center for Clinical Biostatistics and Epidemiology, University
of Pennsylvania School of Medicine, Philadelphia, PA, USA; 3Pﬁzer Inc., New York City, NY, USA; 4University of Southern California, Los
Angeles, CA, USAvhe_447 489..497
ABSTRACT
Objective: We sought to determine lifetime costs, morbidity, and mortality
associated with varying adherence to antihypertensive and 3-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors (statin) therapy in a
hypertensive population.
Methods: A model was constructed to compare costs and outcomes under
three adherence scenarios: no treatment, ideal adherence, and real-world
adherence. Simulated patients’ characteristicsmatched those of participants
in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm
and event probabilities were calculated with Framingham Heart Study risk
equations. The real-world adherence scenario employed adherence data
fromanobservational study of aUS population; risk reductions at each level
of adherence were based on linear extrapolations from clinical trials.
Outputs included life expectancy, frequencies of primary and secondary
coronary heart disease and stroke, and direct medical costs in 2006 US$.
The incremental cost per life-year gained and incremental cost per event
avoided were calculated comparing the three adherence scenarios.
Results: Mean life expectancy was 14.73 years (no-treatment scenario),
15.07 (real-world adherence), and 15.49 (ideal adherence). The average
number of cardiovascular events per patients was 0.738 (no treatment),
0.610 (real-world adherence), and 0.441 (ideal adherence). The incremen-
tal cost of real-world adherence versus no treatment is $30,585 per life-
year gained, and ideal adherence versus real-world adherence is $22,121
per life-year gained.
Conclusions: Hypertensive patients taking antihypertensive and statin
therapy at real-world adherence levels can be expected to receive approxi-
mately 50% of the potential beneﬁt seen in clinical trials. Depending on
its cost, the incremental beneﬁts of an effective adherence intervention
program could make it an attractive value.
Keywords: adherence, antihypertensive, cardiovascular disease, drug com-
bination, dyslipidemia, economic analysis, statin.
Introduction
Numerous clinical trials and meta-analyses have demonstrated
the beneﬁts of antihypertensive medications and 3-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors (statins) for
reducing coronary heart disease (CHD) and stroke risk in
patients at a high risk of CHD [1–4]. A substudy of the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT), ASCOT–Lipid-
Lowering Arm (ASCOT–LLA), recently showed a lower
cardiovascular event incidence among hypertensive patients with
total cholesterol 6.5 mmol/L (241 mg/dl) who were treated
concomitantly with antihypertensive and statin therapies com-
pared with antihypertensive therapy alone [5]. Economic analy-
ses consistently show antihypertensive and statin therapies to be
cost-effective in a myriad of patient populations for both primary
and secondary prevention [6–13]. Efﬁcacy estimates are typically
drawn from clinical trials, where close monitoring encourages
optimal drug adherence (accurate timing, dosage, and frequency
of medication administration) and persistence (duration of
therapy) [14].
In real-world patient-care settings, however, adherence and
persistence fall short of clinical trial levels. Previous studies have
reported suboptimal persistence and adherence among patients
taking antihypertensives [15–17] and statins [18–23] alone or
concurrently. For example, one study of concurrent therapy
found that after 3 months, <45% of patients were adherent to
both regimens; after 6 months <36% were adherent [22].
Although most clinicians and policymakers would agree that
such use is suboptimal, the clinical and economic impacts of
nonadherence with these medications have not been well
described.
To inform policies and practices that might affect adherence
and persistence with antihypertensive and statin therapies, we
assessed the clinical and economic burden of nonadherence in an
adult hypertensive population with normal to mildly elevated
serum cholesterol levels (modeling that of the ASCOT–LLA
population [5].
Methods
Model Structure
Three Markov models were developed to compare costs and
outcomes of primary and secondary prevention with antihyper-
tensive and statin therapy in hypertensive patients aged 40 to 79
years with total cholesterol 6.5 mmol/L (241 mg/dl) to simu-
late the ASCOT–LLA population [5]. Costs and events were
estimated using Monte Carlo microsimulation for three sce-
narios: no treatment, real-world adherence, and ideal adherence.
The no-treatment scenario was a disease natural history model,
including neither costs nor beneﬁts of pharmacologic therapy.
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The ideal adherence scenario was based on the antihypertensive
and statin adherence and effectiveness observed in ASCOT–LLA
[5]. The real-world adherence scenario employed real-world
adherence rates and transitions based on ﬁlled prescription
records from the California Medicaid (Medi-Cal) system.
The base-case analysis compared event rates and costs among
the three models over a lifetime horizon using 1-year Markov
cycles. Events included primary and secondary myocardial inf-
arction (MI) or CHD death, primary and secondary angina
(angina pectoris or unstable angina), and primary and secondary
stroke (any type). The model employed a payer perspective,
including direct pharmacy and medical costs in 2006 US$ with
future costs and beneﬁts discounted by 3% annually [24]. The
models were constructed and analyzed using TreeAge Pro 2006
(TreeAge Software Inc., Williamstown, MA).
Health States
Each model included eight health states: baseline (no CHD
history), angina, MI, stroke, postangina, post-MI, poststroke,
and dead (Fig. 1). Patients remained in the baseline state until a
CHD or stroke event or death due to noncardiovascular causes
(noncardiovascular death). Patients surviving the year in which
an event occurred transitioned to the corresponding postevent
state, where they remained until incurring a subsequent event of
any type or noncardiovascular death.
Event Risks
Natural history event rates were determined annually using sex-
speciﬁc equations from the Framingham Heart Study for primary
and secondary CHD [25] and primary stroke [26]. The equa-
tions’ end points of MI, sudden CHD death, and nonsudden
CHD death were classiﬁed as MI or CHD death in the models;
angina pectoris and coronary insufﬁciency were classiﬁed
as angina [25]. Because no Framingham equation estimates sec-
ondary stroke risk, the annual risk was calculated as the primary
stroke risk multiplied by the relative risk for recurrent stroke
[27].
The Framingham equations’ risk-factor inputs were ran-
domly drawn for each subject in the microsimulation from
probability distributions. All distributions were based on
ASCOT–LLA characteristics except atrial ﬁbrillation, drawn
from the Framingham stroke population [28], and menopause.
Binomial distributions were created for the prevalence of male
sex, cigarette smoking, diabetes mellitus, left ventricular hyper-
trophy, stroke history, and previous cardiovascular disease
(CVD) (excluding stroke and CHD); a normal distribution for
alcohol consumption was created based on the reported mean
and SD from ASCOT–LLA data. Correlations among age, sys-
tolic blood pressure (SBP), total cholesterol and high-density
lipoprotein (HDL) cholesterol were estimated based on a patient
sample from the National Health and Nutritional Examination
Survey 2003 to 2004 [29] that approximated ASCOT–LLA
inclusion criteria, except the requirement of 3 cardiovascular
risk factors, which could not be reproduced [5]. Sex-speciﬁc
hypothetical sets of the four variables were created based on age
distributions from ASCOT–LLA and were randomly assigned to
patients entering the model.
Risk-factor values were held constant over Markov cycles
with the exception of age, which increased with time; meno-
pause, which was assumed to affect all female patients at the age
of 51 years [30], and history of CVD, which was adjusted with
event occurrences.
Mortality
All-cause mortality rates were based on age- and sex-speciﬁc US
life tables [31]. Rates for the baseline state were adjusted by
removing the portion attributable to CHD and stroke for that
age [32].
In-hospital mortality following MI was age-speciﬁc, based on
age distributions and mortality probabilities [33] coupled with
age-speciﬁc hazard ratios for in-hospital mortality [34]. The mor-
tality rate among patients surviving after hospitalization was
equal to the general rate, adjusted for the relative risk of mortal-
ity following MI. Relative risks, conditional on age and years
since MI, were extracted from post-MI survival curves [34].
Poststroke mortality rates were calculated similarly using
published survival curves [35]. Because of limited data being
available, no differentiation was made between in-hospital mor-
tality and mortality for 1 year following stroke. Poststroke mor-
tality rates were functions of age and years since stroke (<5 years;
year 5 rate was applied subsequently).
Mortalities occurring in the year following MI or stroke were
attributed to that event; all other mortalities were classiﬁed as
noncardiovascular deaths. Mortality rates for patients in the
postangina state were assumed to follow general population
rates.
Costs
The models incorporated emergency, hospitalization, physician,
and follow-up direct medical costs associated with included
events (Table 1). Emergency costs for angina and for MI were
based on a study by Russell et al. [36]; separate costs reported for
unstable angina and angina pectoris were averaged using relative
frequency weights [25]. Emergency costs for stroke were not
available from the literature and were conservatively assumed to
be $0.
Hospitalization costs were the national median 2006 Medi-
care reimbursement for the appropriate diagnosis-related group
[37–39], and associated physician reimbursement estimates were
based on Miller and Welch [40], updated to 2006 units [41].
Hospitalization and physician costs for nonfatal MI were an
Figure 1 Model ﬂow diagram. MI, myocardial infarction.
490 Cherry et al.
average of corresponding diagnosis-related groups, weighted by
the relative frequency of Medicare claims [39]. Costs for stroke
subtypes were averaged using literature-based relative frequency
weights [28,42].
Annual pharmacy costs for antihypertensive and statin
therapy were calculated as the daily 2006 wholesale acquisition
cost (WAC) [43] of ASCOT drugs multiplied by 360 days.
ASCOT–Blood Pressure LoweringArm (ASCOT–BPLA) random-
ized patients to two antihypertensive regimens: amlodipine fol-
lowed by perindopril and doxazosin, or atenolol followed by
bendroﬂumethiazide and doxazosin; all agents were available in
two strengths [45]. Antihypertensive cost was an average of the
two regimens, assuming patients took higher-strength amlodipine
or atenolol, and that patients were evenly distributed between
doses of the other drugs. Statin costs were based on ASCOT–LLA
regimen of 10 mg atorvastatin [5].
All costs were deﬁned as distributions and sampled every
cycle. For pharmacy costs, triangular distributions were created
as WAC  20%, chosen for upper costs corresponding to the
average wholesale price [43]. For Medicare-based costs, triangu-
lar distributions were created around the means with bounds at
25th and 75th reimbursement percentiles. Distributions were
deﬁned for all other event-related costs in the same proportion.
Medication Adherence and Persistence
The approach to modeling use of antihypertensive and statin
medications differed across the no treatment, ideal adherence,
and real-world adherence scenarios. The no-treatment model
projected the natural history of CHD and stroke in the absence of
treatment and formed the foundation for the other models.
The ideal adherence scenario extended the no-treatment
scenario by adding antihypertensive and statin therapy and the
associated relative event risk reductions and costs. It was
assumed that adherence rates observed in clinical trials repre-
sented the gold-standard (ideal) adherence for a real-world prac-
tice setting. To model adherence beneﬁts, predicted event risks
were multiplied by relative risk reductions expected with full
adherence to antihypertensive and statin therapy. In ASCOT–
LLA, there was no placebo group; the relative risk for patients
taking antihypertensive and lipid-lowering therapy compared
with those taking only antihypertensives was 0.64 for MI
or CHD death and 0.73 for stroke over the 3.5-year follow-up
[5]. To determine the relative risk under ideal adherence to anti-
hypertensives and statins compared with patients on no treat-
ment, we multiplied the ASCOT–LLA effect estimates by relative
risks from a meta-analysis of placebo-controlled trials of antihy-
pertensive therapy [1], resulting in relative risks of 0.56 for MI
or CHD death, and 0.50 for stroke. Although ASCOT–LLA
reported risk reductions for angina alone, these risk reductions
were unavailable from meta-analyses. Thus, risk reductions with
therapy for angina were assumed to follow those for MI or CHD
death.
Pharmacy costs in the ideal adherence scenario were equal to
1 year’s therapy multiplied by the proportion of days covered
Table 1 Cost inputs
Component
Cost inputs (2006 US$)*
Source referenceBase-case Lower bound† Upper bound†
Nonfatal MI 19,585 18,171 22,152
Emergency 1,456 1,351 1,647 [36]
Hospitalization 7,768 7,207 8,786 [37–39]
Physician 1,244 1,155 1,408 [39–41]
Follow-up in year 1 9,117 8,459 10,312 [36]
Fatal MI 28,762 26,686 32,533
Emergency 1,606 1,490 1,817 [36]
Hospitalization 8,322 7,721 9,413 [37–40]
Physician 1,010 937 1,142 [40,41]
Follow-up in year 1‡ 17,824 16,538 20,161 [36]
Primary angina 5,155 4,738 5,831
Emergency 433 402 490 [36]
Hospitalization 2,763 2,564 3,126 [37–39]
Physician 573 532 648 [40,41]
Follow-up in year 1 1,385 1,285 1,567 [36]
Secondary angina 7,881 7,312 8,914
Emergency 497 461 562 [36]
Hospitalization 2,763 2,564 3,126 [37–39]
Physician 573 532 648 [40,41]
Follow-up in year 1 4,048 3,756 4,578 [36]
Primary stroke 41,382 38,395 46,807
Emergency — — —
Hospitalization 6,097 5,657 6,896 [37–39]
Physician 1,030 955 1,165 [40,41]
Annual institutional care (years 1 and 2)§ 34,255 31,783 38,746 [42]
Secondary stroke 49,761 46,169 56,284
Emergency — — —
Hospitalization 6,097 5,657 6,896 [37–39]
Physician 1,030 955 1,165 [40,41]
Annual institutional care (years 1 and 2)§ 42,634 39,557 48,223 [42]
Post-CHD per year 1,217 1,129 1,377 [36]
Annual statin therapy 832 666 999 [43]
Annual antihypertensive therapy 859 687 1031 [43]
Annual discount 3% — — [23]
*All costs were inﬂated to 2006 US$ using the Medical Care Consumer Price Index for all urban consumers [44].
†Bounds for the annual cost of statin and antihypertensive therapy are base-case values 20%. Bounds for all other costs are the 25th and 75th percentiles from the distribution of Medicare
hospital reimbursement for 2006.
‡Follow-up costs in year 1 apply only to patients surviving hospitalization.
§Institutional care costs for stroke are age- and sex-speciﬁc; the reported costs are mean values.
CHD, coronary heart disease; MI, myocardial infarction.
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(PDC) observed in the BPLA of ASCOT, ASCOT–BPLA [45] (for
antihypertensives), and in ASCOT–LLA [5,6] (for statins).
The real-world adherence scenario was similar to the ideal
adherence scenario but added real-world adherence data and
costs and beneﬁts associated with each level of adherence. For
simplicity, we deﬁned three possible levels of adherence and
allowed patients to transition among them over time: adherent
(PDC  80%); partially adherent (20%  PDC < 80%); and
nonadherent (PDC < 20%) [18]. Adherence status was treated
independently for antihypertensives and statin therapy, resulting
in nine possible adherence states. All nondead health states from
the natural history model were subdivided into these nine states
to account for adherence status.
Initial adherence status and transitions among categories
of adherence were drawn from an analysis of prescription and
medical claims data from Medi-Cal. A sample of 8277 patients
initiating antihypertensive and statin therapies within a 180-day
period were extracted, using ﬁrst prescription claim date as the
index date. Patients were aged 40 years, with a diagnosis of
hypertension, and no history of CHD, stroke, or diabetes in the
6 months prior to the index date. Patients were followed for up
to 6 years or until death or data stream termination. An adher-
ence transition matrix was determined empirically for each year
of therapy. The initial and ﬁnal adherence status distributions
and transition probabilities for years 1 to 2 are reported, as an
example, in Table 2. The transition probabilities for year 6 and
beyond equaled those for years 5 to 6, as adherence had stabi-
lized at this point.
Annual event risks predicted by Framingham equations were
multiplied by the relative risk for each adherence category
(Table 3). Relative risk reductions for patients adherent to both
antihypertensive and statin therapy equaled those used in the
ideal adherence scenario. For patients fully adherent to one medi-
cation and nonadherent to the other, relative risk reductions were
based on meta-analyses of placebo-controlled trials of antihyper-
tensive [1] and statin [2–4] therapies.
As data were lacking for the effectiveness achieved by par-
tially adherent patients, a linear association between adherence
and efﬁcacy was assumed in the base-case analysis. The efﬁcacy
of partial adherence was thus derived as the midpoint of known
relative risks. For example, the relative risk of stroke for patients
fully adherent to antihypertensive therapy, and partially adherent
to statin therapy (fully adherent/partially adherent) equaled the
mean relative risk for fully adherent/nonadherent (0.68) and fully
adherent/fully adherent (0.54), or 0.61) (see Table 3 for explana-
tory calculations). Pharmacy costs in this scenario equaled 1-year
therapy costs multiplied by the actual PDC. As parameters in
the model, PDCs were deﬁned as b-distributions derived from
observed means and SDs. For antihypertensives, mean  SD
PDC for: full adherence was 94.1  6.0%; partial adherence,
52.9  17.2%; and nonadherence, 12.0  4.8%. For statins,
PDC for: full adherence was 92.5  6.2%; partial adherence,
50.3  17.4%; and nonadherence, 11.9  4.7%.
Analyses
Monte Carlo microsimulations were performed for each sce-
nario, and events, costs, and patient-years were recorded. The
model considered a lifetime horizon, such that each simulation
ran until death. Each model ran 10 times with 50,000 trials
(patients) to enable variability analyses.
As a primary analysis, the incremental cost-effectiveness ratio
(ICER) per life-year gained was calculated between the ideal and
real-world adherence scenarios. Additional analyses included the
ICER per life-year gained between the real-world adherence and Ta
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no-treatment scenarios, and calculations of ICERs per event
avoided. Mean ICER and the 95% conﬁdence interval (CI) were
calculated for each analysis.
Additional simulations assessed the signiﬁcance of risk reduc-
tion associated with partial adherence. The base-case analysis
assumed that partial adherence yielded 50% of the effectiveness
of full adherence. The percentage of full adherence effectiveness
seen with partial adherence was varied from 0% (no effective-
ness, equivalent to no treatment) to 100% (full effectiveness,
equivalent to full adherence). Two-way sensitivity analyses were
conducted to examine the inﬂuence of partial adherence effec-
tiveness when segmenting by starting age.
Results
Base-Case Analysis
Baseline model patient characteristics approximated those of the
ASCOT–LLA participants, except mean age (58.7 years vs.
ASCOT–LLA: 63.1 years), SBP (150.7 mm Hg vs. ASCOT–
LLA: 164.2 mm Hg), total cholesterol (199.8 mg/dl vs. ASCOT–
LLA 5.5 mmol/L [211.5 mg/dl]), and HDL cholesterol
(48.8 mg/dl vs. ASCOT–LLA 1.3 mmol/L [50.0 mg/dl]), all of
which were lower in the model than in ASCOT–LLA by <10%
(Table 4). This resulted in slightly lower population-level event
risks.
Mean life expectancy, discounted by 3% per year, was 14.73
years (95% CI 14.71–14.75) for the no-treatment scenario,
15.07 years (95% CI 15.06–15.08) for real-world adherence,
and 15.49 years (95% CI 15.47–15.51) for ideal adherence.
Mean frequency of events per patient were 0.738 (95% CI
0.737–0.740) for the no-treatment scenario, 0.610 (95% CI
0.608–0.612) for real-world adherence, and 0.441 (95%
CI 0.440–0.442) for ideal adherence.
Effectiveness and cost-effectiveness results are provided in
Table 5. Lifetime discounted direct medical costs per patient were
$12,831 (95% CI 12,785–12,877) for the no-treatment scenario,
$23,295 (95% CI 23,270–23,321) for real-world adherence, and
$32,492 (95% CI 32,462–32,522) for ideal adherence. Com-
pared with real-world adherence, ideal adherence was associated
with an additional $9197 and 0.42 patient-years, giving an ICER
of $22,121 per life-year gained (95% CI 21,067–23,176). In the
ideal adherence scenario, there were 0.17 fewer events per
patient than in the real-world adherence scenario, yielding an
ICER per event avoided of $54,364 (95% CI 53,493–55,234).
Compared with no treatment, real-world adherence was asso-
ciated with an additional $10,464 and 0.35 patient-years, giving
an ICER of $30,586 per life-year gained (95% CI 28,742–
32,431). Patients in the real-world adherence scenario incurred
0.13 fewer events than those in no treatment, giving an ICER of
$81,591 per event avoided (95% CI 80,353–82,830).
Risk Reduction with Real-World Adherence
The ICER per life-year gained for ideal versus real-world adher-
ence was modestly sensitive to assumptions about the drugs’
effectiveness under partial adherence. When partial adherence
was assumed to yield 0% of full effectiveness, the ICER
decreased from $22,121 (base-case) to $16,153 (95% CI
15,664–16,642). Conversely, when partial adherence was
assumed to yield 100% of full effectiveness, the ICER increased
to $32,529 (95% CI 29,854–35,205). The ICER per event
avoided between the ideal and real-world adherence scenarios
showed similar sensitivity, varying between $41,005 (95% CI
40,000–42,011) and $76,763 (95% CI 75,272–78,254).
Figure 2 shows ICER per life-year gained between the ideal
and real-world adherence scenarios as a function of effectiveness
Table 3 Relative risks of coronary heart disease and stroke by adherence status
Antihypertensive adherence Statin adherence
Relative risks (95% CI)
CalculationCHD Stroke
Full Full 0.50 (0.39–0.65) 0.54 (0.41–0.71) A
Full Partial 0.68 0.61 B
Full Non 0.87 (0.80–0.94) 0.68 (0.61–0.76) C
Partial Full 0.59 0.66 D
Partial Partial 0.76 0.75 E
Partial Non 0.94 0.84 F
Non Full 0.69 (0.64–0.74) 0.79 (0.73–0.85) G
Non Partial 0.85 0.90 H
Non Non 1.00 1.00 I
Calculation A: Relative risk of (Full–Full) to (Full–Non) [5] times the mean of the relative risk of (Full–Non) to (Non–Non) [1] and the relative risk of (Non–Full) to (Non–Non) [2,3].
Conﬁdence interval calculated as proportionate to wider of two source conﬁdence intervals [5].
Calculation B: Mean of (Full–Full) and (Full–Non).
Calculation C: Relative risks and conﬁdence intervals as reported in antihypertensive meta-analysis [1].
Calculation D: Mean of (Full–Full) and (Non–Full).
Calculation E: Mean of (Full–Full), (Full–Non), (Non–Full), and (Non–Non).
Calculation F: Mean of (Full–Non) and (Non–Non).
Calculation G: Relative risks and conﬁdence intervals as reported in meta-analyses of statins in CHD prevention [2] and stroke prevention [3].
Calculation H: Mean of (Non–Full) and (Non–Non).
Calculation I: Referent.
CHD, coronary heart disease; CI, conﬁdence interval.
Table 4 Patient characteristics at baseline
Patient characteristic
Mean (across all treatment
scenarios)*
Age (years) 58.7 (10.3)
Alcohol consumption (oz/week) 12.2 (7.6)
Systolic blood pressure (mm Hg) 150.7 (8.8)
Total cholesterol (mg/dl) 199.8 (29.8)
HDL cholesterol (mg/dl) 48.8 (13.5)
Male (%) 81.1
Current smoker (%) 33.2
Diabetes (%) 24.3
LVH-ECG (%) 14.5
Atrial ﬁbrillation (%) 2.8
History of CVD† (%) 8.6
*Includes no treatment, ideal adherence, and real-world adherence.
†Excludes coronary heart disease and stroke.
Data are shown as % or mean (standard deviation).
CVD, cardiovascular disease; HDL, high-density lipoprotein; LVH-ECG, left ventricular hyper-
trophy by electrocardiogram.
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in the partial-adherence state and patients’ age at baseline. ICERs
were lower for older patients, from $11,214 (95% CI 10,530–
11,897) to $24,934 (95% CI 23,346–26,522) among patients
aged 65 years, and $19,144 (95% CI 18,210–20,079) to
$35,532 (95% CI 32,333–38,731) among patients aged 45 to 54
years. Figure 3 shows the same analysis of ICER per event
avoided between ideal and real-world adherence scenarios. As
with life-years gained, ICERs per event avoided were lower
with increasing age, from $34,636 (95% CI 32,665–36,607) to
$70,915 (95% CI 67,614–74,215) among patients aged 65
years, and $43,875 (95% CI 42,550–45,200) to $79,635 (95%
CI 75,205–84,065) among patients aged 45 to 54 years.
Discussion
Nonadherence to concomitant antihypertensive and statin
therapy undermines the drugs’ potential effectiveness in prevent-
ing cardiovascular events. We estimated the population-level
events and lost life-years attributable to nonadherence and, con-
sequently, the reduction in events and increase in life expectancy
that could be realized through improved adherence.
Among a hypertensive population with multiple cardiovascu-
lar risk factors, real-world adherence to antihypertensive and
statin therapy added 4.2 months to life expectancy compared
with no treatment. Assuming ideal adherence as seen in clinical
trials, the life expectancy gain versus no treatment was 9.2
months. Accordingly, real-world adherence foregoes ~54% of life
expectancy gained from ideal adherence. For a population of
10,000 patients, 6100 lifetime CHD and stroke events would be
expected at real-world adherence. At ideal levels of adherence,
1700 of those events (28%) could be avoided.
Because lower adherence also reduced overall treatment
costs, it is important to translate these ﬁndings into terms that
consider both costs and treatment beneﬁts. At $30,586 and
$22,121 per life-year gained, we found treatment at both real-
world and ideal adherence to be cost-effective by conventional
standards [46]. Moreover, our analytic framework can be used to
evaluate the cost-effectiveness of adherence interventions: from a
payer’s perspective, increasing adherence to ideal levels with a
program costing up to ~$8400 per patient would be as cost-
effective as initiating this number of patients on dual-therapy at
real-world adherence, while also conferring absolute beneﬁts in
life expectancy and event reduction.
Medication effectiveness at partial adherence levels was the
greatest source of uncertainty in the models. Our sensitivity
analyses showed, however, that evenin the case where partial
Table 5 Incremental cost-effectiveness ratios over lifetime
Adherence scenario
Average Incremental
ICER (95% CI)Costs* Patient-years* Costs* Patient-years*
No treatment 12,831 14.73 — — — —
Real-world 23,295 15.07 10,464 0.35 30,586 (28,742–32,431)
Ideal 32,492 15.49 9,197 0.42 22,121 (21,067–23,176)
Costs* Events Costs* Events
No treatment 12,831 0.74 — — — —
Real-world 23,295 0.61 10,464 -0.13 81,591 (80,353–82,830)
Ideal 32,492 0.44 9,197 -0.17 54,364 (53,493–55,234)
*Discounted by 3% annually.
All costs 2006 US$.
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio.
Figure 2 Incremental cost-effectiveness ratio per
life-year gained for ideal versus real-world adher-
ence for varying partial adherence effectiveness.
USD, United States Dollars.
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adherence yields the same beneﬁts as full adherence, there exist
cost-effective, population-level gains to be made through
increased adherence. These potential gains increase with decreas-
ing levels of partial adherence effectiveness, as the beneﬁt gap
between the ideal and real-world adherence scenarios widens.
The modeling methodology employed in the present study is an
important innovation because of the biases that are inherent in
post hoc analyses when estimating the effects of adherence in
clinical trials [47]. In the present article, we have tried to avoid
such biases by constructing upper and lower bounds of effective-
ness based on the treatment and placebo groups of trials, then
adjusted for nonadherence using an “interpolation” between
these groups based on real-world levels of adherence.
Our analysis must be interpreted in light of its limitations,
including assumptions on adherence rates after a CHD event,
the short-term interaction of adherence and effectiveness, and
extrapolations of long-term effectiveness of antihypertensive and
statin therapy. Adherence data were derived from the California
Medicaid (Medi-Cal) system, which may not represent other
segments of the population. We were unable to estimate the
emergency cost of stroke events in the United States, which
caused us to underestimate one aspect of the cost of nonadher-
ence and thus to underestimate the cost-effectiveness of improv-
ing adherence to ideal levels. Conversely, amlodipine lost patent
protection in the United States in 2007 and can now be acquired
at a lower cost than the 2006 ﬁgure in our model. Amlodipine,
however, was one of only ﬁve antihypertensives used by patients
in the model, so the impact of this price change would not have
affected the average daily WAC of antihypertensive therapy sig-
niﬁcantly. To the extent that we overestimated the cost of anti-
hypertensive therapy, our results are conservative in that the cost
per event prevented is actually lower and the cost-effectiveness of
improving adherence is improved.
Assessing adherence based on prescription reﬁll rates and the
PDC may overestimate actual dosing accuracy because it assumes
that patients take all of the medications for prescriptions that are
ﬁlled. Prescription reﬁll ratesl, however, have been shown to be
closely associated with other measures of adherence, including
serum drug levels and physiologic drug effects [48]. A given day
was assumed to be covered if any drug for the indication of
interest was available. Such an approach is likely to be accurate
for lipid-lowering therapy, which in most patients consists of
statins alone. For the treatment of hypertension, however, use of
multiple drug regimens is common and we may have overesti-
mated adherence with this method.
Our model did not consider the cost of an intervention that
would be required to improve adherence; this cost would directly
increase the ICER of improved adherence and thus, future studies
are needed to consider the cost-effectiveness of speciﬁc adherence
interventions. The model also assumed that a change in adher-
ence resulted in a change in event risk within 1 year, as patients
were assigned relative event risks based on current adherence
status. ASCOT–LLA reported that the risk-reduction beneﬁt of
dual therapy, compared with antihypertensive monotherapy,
emerged within 1 year [5], suggesting that the gains from ideal
adherence may be recognized within the models’ 1-year cycles.
The duration of effects following discontinuation of or reduced
adherence to medication is unknown, however, and patients may
continue to see beneﬁts after stopping therapy. In this case, the
real-world adherence scenario may have underestimated popula-
tion risk reduction because most patients’ adherence deteriorates
over successive model cycles. A ﬁnal limitation is the coupling of
shorter-term data with a lifetime horizon. Simulated model
patients survived 15 years on average, longer than the duration
of any trial from which effectiveness estimates were drawn. A
clinical trial of statins supported this assumption by demonstrat-
ing that risk reductions persisted in older patients [49].
In summary, we found that in patients with hypertension and
multiple cardiovascular risk factors, more than half of the poten-
tial beneﬁts from antihypertensive and statin therapies are lost to
poor adherence. Antihypertensive and statin therapies are cost-
effective at adherence levels seen in real-world settings but are
more cost-effective when taken at levels seen in clinical trials.
Depending on its cost, an intervention that improved adherence
from typical to trial levels has the potential to be an attractive use
of health-care resources.
This study was sponsored by Pﬁzer Inc. Editorial support was provided by
Karen Burrows of Envision Pharma and funded by Pﬁzer Inc.
Source of ﬁnancial support: This study was sponsored by Pﬁzer Inc.
Figure 3 Incremental cost-effectiveness ratio per
event avoided for ideal versus real-world adher-
ence scenarios with varying partial adherence
effectiveness. USD, United States Dollars.
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